GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group A/S (OCSE:PEG) » Definitions » EPS (Diluted)

Pharma Equity Group A/S (OCSE:PEG) EPS (Diluted) : kr-0.03 (TTM As of Mar. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group A/S EPS (Diluted)?

Pharma Equity Group A/S's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was kr-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-0.03.

Pharma Equity Group A/S's EPS (Basic) for the three months ended in Mar. 2024 was kr-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-0.03.

Pharma Equity Group A/S's EPS without NRI for the three months ended in Mar. 2024 was kr-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was kr-0.03.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Pharma Equity Group A/S EPS (Diluted) Historical Data

The historical data trend for Pharma Equity Group A/S's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group A/S EPS (Diluted) Chart

Pharma Equity Group A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.70 -1.04 0.10 -0.01 -0.02

Pharma Equity Group A/S Quarterly Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -0.01 -0.01

Competitive Comparison of Pharma Equity Group A/S's EPS (Diluted)

For the Biotechnology subindustry, Pharma Equity Group A/S's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Equity Group A/S's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group A/S's PE Ratio distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group A/S's PE Ratio falls into.



Pharma Equity Group A/S EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Pharma Equity Group A/S's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-24.609-0)/1088.551
=-0.02

Pharma Equity Group A/S's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-7.17-0)/1039.497
=-0.01

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharma Equity Group A/S  (OCSE:PEG) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Pharma Equity Group A/S EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group A/S's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Equity Group A/S (OCSE:PEG) Business Description

Traded in Other Exchanges
N/A
Address
Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970
Pharma Equity Group A/S is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develops technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement.